Alvotech
Better Access. Better Lives.
We are led by science, driven by passion, and committed to biosimilars. We are continually evaluating additional pipeline opportunities to bring a strategic and robust selection of treatment options to patients around the world.
AVT02
- Biosimilar candidate
- High-concentration, low-volume adalimumab
- Reference biologic
- HUMIRA®
- Therapeutic area
- Immunology
Approved by
- European Commission
- Health Canada
- MHRA
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT04
- Biosimilar candidate
- ustekinumab
- Reference biologic
- STELARA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT23*
- Biosimilar candidate
- omalizumab
- Reference biologic
- XOLAIR®
- Therapeutic area
- Respiratory
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT03
- Biosimilar candidate
- denosumab
- Reference biologic
- PROLIA®/XGEVA®
- Therapeutic area
- Immunology/Oncology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT05
- Biosimilar candidate
- golimumab
- Reference biologic
- SIMPONI®/SIMPONI ARIA®
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT06
- Biosimilar candidate
- aflibercept
- Reference biologic
- EYLEA®
- Therapeutic area
- Ophthalmology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT16
- Biosimilar candidate
- undisclosed
- Reference biologic
- undisclosed
- Therapeutic area
- Immunology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
AVT33
- Biosimilar candidate
- undisclosed
- Reference biologic
- undisclosed
- Therapeutic area
- Oncology
- Early Phase
- Pre-clinical
- Clinical Trials
- Filing
- Approval
- Launch
*Licenced from Biosana.
HUMIRA is registered trademark of AbbVie Inc.
STELARA, SIMPONI and SIMPONI ARIA are registered trademarks of Janssen Biotech Inc.
XOLAIR is a registered trademark of Novartis AG.
PROLIA and XGEVA are registered trademarks of Amgen Inc.
EYLEA is a registered trademark of Regeneron Pharmaceuticals Inc.